JPS609697B2 - 製剤 - Google Patents

製剤

Info

Publication number: JPS609697B2
Authority: JP; Japan
Prior art keywords: resin; coating; drug; particles; coated
Prior art date: 1976-11-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP52140093A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5369822A (en

Inventor

イエグナスワニ・ラグフナタン

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pennwalt Corp

Original Assignee

Pennwalt Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-11-26

Filing date

1977-11-24

Publication date

1985-03-12

1977-11-24 Application filed by Pennwalt Corp filed Critical Pennwalt Corp

1978-06-21 Publication of JPS5369822A publication Critical patent/JPS5369822A/ja

1985-03-12 Publication of JPS609697B2 publication Critical patent/JPS609697B2/ja

Status Expired legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 55
238000009472 formulation Methods 0.000 title claims description 36
238000000576 coating method Methods 0.000 claims description 106
239000011248 coating agent Substances 0.000 claims description 101
239000002245 particle Substances 0.000 claims description 84
229940079593 drug Drugs 0.000 claims description 69
239000003814 drug Substances 0.000 claims description 69
239000000805 composite resin Substances 0.000 claims description 64
229960000395 phenylpropanolamine Drugs 0.000 claims description 46
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 45
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 45
238000002360 preparation method Methods 0.000 claims description 30
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 27
239000001856 Ethyl cellulose Substances 0.000 claims description 26
229920001249 ethyl cellulose Polymers 0.000 claims description 26
235000019325 ethyl cellulose Nutrition 0.000 claims description 26
239000002202 Polyethylene glycol Substances 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 18
229920001223 polyethylene glycol Polymers 0.000 claims description 18
229960001985 dextromethorphan Drugs 0.000 claims description 16
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 15
238000009792 diffusion process Methods 0.000 claims description 14
230000002401 inhibitory effect Effects 0.000 claims description 14
239000011246 composite particle Substances 0.000 claims description 6
239000003456 ion exchange resin Substances 0.000 claims description 6
229920003303 ion-exchange polymer Polymers 0.000 claims description 6
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
229920005989 resin Polymers 0.000 description 67
239000011347 resin Substances 0.000 description 67
229920001429 chelating resin Polymers 0.000 description 56
238000004090 dissolution Methods 0.000 description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 27
239000008367 deionised water Substances 0.000 description 20
229910021641 deionized water Inorganic materials 0.000 description 20
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 19
238000002156 mixing Methods 0.000 description 18
DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 17
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
229960002179 ephedrine Drugs 0.000 description 14
235000015112 vegetable and seed oil Nutrition 0.000 description 14
239000008158 vegetable oil Substances 0.000 description 14
239000000463 material Substances 0.000 description 13
229940057838 polyethylene glycol 4000 Drugs 0.000 description 13
239000002904 solvent Substances 0.000 description 11
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
229960003562 phentermine Drugs 0.000 description 10
150000003839 salts Chemical class 0.000 description 9
238000000034 method Methods 0.000 description 8
238000003756 stirring Methods 0.000 description 8
239000002131 composite material Substances 0.000 description 7
210000001035 gastrointestinal tract Anatomy 0.000 description 7
239000002775 capsule Substances 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
239000011162 core material Substances 0.000 description 5
239000012738 dissolution medium Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
238000013265 extended release Methods 0.000 description 5
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
229960003908 pseudoephedrine Drugs 0.000 description 5
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 5
238000005507 spraying Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
210000002700 urine Anatomy 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000036765 blood level Effects 0.000 description 4
238000005342 ion exchange Methods 0.000 description 4
238000011068 loading method Methods 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
102100030130 Interferon regulatory factor 6 Human genes 0.000 description 3
101710157822 Interferon regulatory factor 6 Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229940127230 sympathomimetic drug Drugs 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
241000270295 Serpentes Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
235000020375 flavoured syrup Nutrition 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
-1 polyethylene Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
FPXKNYVSOKOLKD-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-chloroaniline Chemical compound OC(=O)\C=C/C(O)=O.ClNC1=CC=CC=C1 FPXKNYVSOKOLKD-BTJKTKAUSA-N 0.000 description 1
QWFMDSOYEQHWMF-UHFFFAOYSA-N 2,3-bis(ethenyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(C=C)=C1C=C QWFMDSOYEQHWMF-UHFFFAOYSA-N 0.000 description 1
LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000252233 Cyprinus carpio Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010013647 Drowning Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000233805 Phoenix Species 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000004851 dishwashing Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910001410 inorganic ion Inorganic materials 0.000 description 1
238000007689 inspection Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
KUDPGZONDFORKU-UHFFFAOYSA-N n-chloroaniline Chemical compound ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 description 1
ABRWESLGGMHKEA-UHFFFAOYSA-N n-tert-butylaniline Chemical compound CC(C)(C)NC1=CC=CC=C1 ABRWESLGGMHKEA-UHFFFAOYSA-N 0.000 description 1
239000005445 natural material Substances 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229920001568 phenolic resin Polymers 0.000 description 1
229960000264 phentermine resin Drugs 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP52140093A 1976-11-26 1977-11-24 製剤 Expired JPS609697B2 (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US74532576A	1976-11-26	1976-11-26
US80010577A	1977-05-24	1977-05-24
US800105		1977-05-24
US745325		1985-06-14

Publications (2)

Publication Number	Publication Date
JPS5369822A JPS5369822A (en)	1978-06-21
JPS609697B2 true JPS609697B2 (ja)	1985-03-12

Family

ID=27114439

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP52140093A Expired JPS609697B2 (ja)	1976-11-26	1977-11-24	製剤

Country Status (21)

Country	Link
JP (1)	JPS609697B2 (fr)
AR (1)	AR218047A1 (fr)
AT (1)	AT359197B (fr)
AU (1)	AU511080B2 (fr)
BE (1)	BE861141A (fr)
CA (1)	CA1086226A (fr)
CH (1)	CH639560A5 (fr)
DE (1)	DE2752728C2 (fr)
DK (1)	DK150534C (fr)
FI (1)	FI65910C (fr)
FR (1)	FR2373288A1 (fr)
GB (1)	GB1544761A (fr)
GR (1)	GR61724B (fr)
IE (1)	IE45998B1 (fr)
IL (1)	IL53462A (fr)
LU (1)	LU78584A1 (fr)
NL (1)	NL182283C (fr)
NO (1)	NO147626C (fr)
NZ (1)	NZ185772A (fr)
PT (1)	PT67323B (fr)
SE (1)	SE426781B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2929456A1 (de)	1979-07-20	1981-02-05	Lentia Gmbh	Zusammensetzung mit verlaengerter broncholytischer und tokolytischer wirksamkeit, ein verfahren zu deren herstellung und broncholytisch und tokolytisch wirkendes mittel
CA1236023A (fr) *	1984-07-18	1988-05-03	Yegnaswami Raghunathan	Preparations pharmaceutiques a liberation controlee
US4692462A (en) *	1985-03-18	1987-09-08	Menley & James Laboratories, Ltd.	Compositions and method of controlling transdermal penetration of topical and systemic agents
US5612059A (en) *	1988-08-30	1997-03-18	Pfizer Inc.	Use of asymmetric membranes in delivery devices
US5188825A (en) *	1989-12-28	1993-02-23	Iles Martin C	Freeze-dried dosage forms and methods for preparing the same
US5876752A (en) *	1990-08-07	1999-03-02	Pfizer Inc.	Use of interfacially-polymerized membranes in delivery devices
US5436011A (en) *	1993-04-16	1995-07-25	Bristol-Myers Squibb Company	Solid pharmaceutical dosage form and a method for reducing abrasion
US20130230587A1 (en) *	2010-11-10	2013-09-05	Rubicon Research Private Limited	Sustained release compositions
FR3059903B1 (fr) *	2016-12-08	2019-03-22	Salsarulo Pharma	Medicament oral comprenant un laxatif osmotique incorpore dans une matrice a base de matieres grasses vegetales
EP3694555A4 (fr) *	2017-10-09	2021-07-07	Rhodes Pharmaceuticals L.P.	Compositions pharmaceutiques à base de résinate, et leurs procédés de fabrication et d'utilisation
WO2020234842A1 (fr) *	2019-05-23	2020-11-26	G.D Societa' Per Azioni	Unité de remplissage pour remplir un récipient, en particulier une cartouche, avec un produit liquide de l'industrie pharmaceutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE550150A (fr) *	1955-08-08
GB843118A (en) *	1957-02-13	1960-08-04	Ici Ltd	Pharmaceutical compositions containing piperidine derivatives
US3158538A (en) *	1961-02-23	1964-11-24	White Lab Inc	Antidiarrheal compositions and method of using
GB982150A (en) *	1961-09-29	1965-02-03	Glaxo Group Ltd	Therapeutic resin complexes
US3594470A (en) *	1968-02-19	1971-07-20	Abbott Lab	Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
GB1218102A (en) *	1968-03-15	1971-01-06	Philips Nv	Improvements in medicaments comprising drug/ion-exchange resin compounds
CA927282A (en) *	1968-09-03	1973-05-29	S. Banker Gilbert	Entrapment compositions and processes
CA935092A (en) *	1968-09-03	1973-10-09	S. Banker Gilbert	Molecular drug entrapment process and compositions
DE2343218C2 (de) *	1973-08-28	1986-08-07	Hoechst Ag, 6230 Frankfurt	Furosemid enthaltende Pellets

1977
- 1977-11-24 BE BE182882A patent/BE861141A/fr not_active IP Right Cessation
- 1977-11-24 IL IL53462A patent/IL53462A/xx unknown
- 1977-11-24 GB GB48997/77A patent/GB1544761A/en not_active Expired
- 1977-11-24 FI FI773568A patent/FI65910C/fi not_active IP Right Cessation
- 1977-11-24 CA CA291,664A patent/CA1086226A/fr not_active Expired
- 1977-11-24 JP JP52140093A patent/JPS609697B2/ja not_active Expired
- 1977-11-24 GR GR54861A patent/GR61724B/el unknown
- 1977-11-24 NZ NZ185772A patent/NZ185772A/xx unknown
- 1977-11-25 AR AR270132A patent/AR218047A1/es active
- 1977-11-25 PT PT67323A patent/PT67323B/pt unknown
- 1977-11-25 NL NLAANVRAGE7712996,A patent/NL182283C/xx not_active IP Right Cessation
- 1977-11-25 DE DE2752728A patent/DE2752728C2/de not_active Expired
- 1977-11-25 FR FR7735611A patent/FR2373288A1/fr active Granted
- 1977-11-25 LU LU78584A patent/LU78584A1/xx unknown
- 1977-11-25 CH CH1450177A patent/CH639560A5/de not_active IP Right Cessation
- 1977-11-25 NO NO774051A patent/NO147626C/no unknown
- 1977-11-25 DK DK523277A patent/DK150534C/da not_active IP Right Cessation
- 1977-11-25 AT AT848077A patent/AT359197B/de not_active IP Right Cessation
- 1977-11-25 AU AU30986/77A patent/AU511080B2/en not_active Expired
- 1977-11-25 IE IE2391/77A patent/IE45998B1/en not_active IP Right Cessation
- 1977-11-25 SE SE7713370A patent/SE426781B/sv not_active IP Right Cessation

Also Published As

Publication number	Publication date
CH639560A5 (en)	1983-11-30
JPS5369822A (en)	1978-06-21
IE45998L (en)	1978-05-26
FI65910C (fi)	1984-08-10
PT67323A (en)	1977-12-01
SE7713370L (sv)	1978-05-27
NO774051L (no)	1978-05-29
PT67323B (en)	1979-04-24
IE45998B1 (en)	1983-01-26
NL7712996A (nl)	1978-05-30
ATA848077A (de)	1980-03-15
SE426781B (sv)	1983-02-14
DE2752728C2 (de)	1985-08-01
BE861141A (fr)	1978-03-16
CA1086226A (fr)	1980-09-23
FR2373288A1 (fr)	1978-07-07
LU78584A1 (fr)	1978-04-20
DE2752728A1 (de)	1978-06-01
NO147626C (no)	1983-05-25
FI65910B (fi)	1984-04-30
AU3098677A (en)	1979-05-31
AR218047A1 (es)	1980-05-15
DK150534C (da)	1987-10-12
FI773568A7 (fi)	1978-05-27
FR2373288B1 (fr)	1980-06-13
NL182283B (nl)	1987-09-16
GR61724B (en)	1978-12-29
DK523277A (da)	1978-05-27
NL182283C (nl)	1988-02-16
DK150534B (da)	1987-03-23
IL53462A (en)	1980-12-31
AT359197B (de)	1980-10-27
IL53462A0 (en)	1978-01-31
NO147626B (no)	1983-02-07
GB1544761A (en)	1979-04-25
NZ185772A (en)	1978-12-18
AU511080B2 (en)	1980-07-24

Publication	Publication Date	Title
US4221778A (en)	1980-09-09	Prolonged release pharmaceutical preparations
Raghunathan et al.	1981	Sustained‐release drug delivery system I: Coated ion‐exchange resin system for phenylpropanolamine and other drugs
US4847077A (en)	1989-07-11	Controlled release pharmaceutical preparations
US11666546B2 (en)	2023-06-06	GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
KR940000100B1 (ko)	1994-01-05	메토프롤롤염을 함유하는 서방형 제제의 제조방법
US5188841A (en)	1993-02-23	Sustained release pharmaceutical formulations
JPH05279247A (ja)	1993-10-26	徐放性液剤
CZ160194A3 (en)	1995-03-15	Solid medicament form with controlled release of active component
EP0519870A1 (fr)	1992-12-23	Nouvelle composition à base de diclofenac pour l'administration orale
EP2645996A2 (fr)	2013-10-09	Procédé de production d'une préparation pharmaceutique contenant un ipp
DK160601B (da)	1991-04-02	Farmaceutisk harpiksholdigt, sustained release praeparat med kontrolleret afgivelse af et farmaceutisk acceptabelt syreadditionssalt af dextromethorphan samt fremgangsmaade til fremstilling deraf
CH696419A5 (de)	2007-06-15	Pharmazeutische Pellets mit Tamsulosin und Verfahren zu deren Herstellung.
SK672003A3 (en)	2003-06-03	Stable salts of o-acetylsalicylic acid with basic amino acids
KR20030009440A (ko)	2003-01-29	조성물
WO2015076821A1 (fr)	2015-05-28	Nouvelle formulation de clonidine
JPS609697B2 (ja)	1985-03-12	製剤
JPH0649645B2 (ja)	1994-06-29	徐放性医薬製剤
WO1989002738A1 (fr)	1989-04-06	Preparation de nifedipine a liberation soutenue
JPH0428685B2 (fr)	1992-05-15
PT99912A (pt)	1993-01-29	Processo para a preparacao de uma composicao farmaceutica oral compreendendo particulas de resina de permuta cationica que contem uma droga de poliamina farmacologicamente activa ligada a referida resina
PT1954251E (pt)	2012-06-06	Composição de libertação prolongada da substância ativa, seu método de preparação e sua utilização
JPS6335526A (ja)	1988-02-16	ポリマ−処理イオン交換樹脂
CA2370355A1 (fr)	2002-08-05	Formulations multiparticulaires de sels de lithium pour administration orale possiblement quotidienne
PL186915B1 (pl)	2004-03-31	Tabletka zawierająca kwas tolfenamowy lub jego farmaceutycznie dopuszczalną sól i sposób wytwarzania takiej tabletki
JPH07500332A (ja)	1995-01-12	イオン交換体を有する新規な薬剤